Neuronetics (STIM) Hisse Özeti
Neuronetics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda nöro-sağlık bozuklukları olan hastalar için ofis içi tedaviler sağlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
STIM Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neuronetics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$3.00 |
| 52 Haftanın En Yüksek Seviyesi | US$3.71 |
| 52 Haftanın En Düşük Seviyesi | US$0.80 |
| Beta | 1.12 |
| 1 Aylık Değişim | 73.41% |
| 3 Aylık Değişim | 145.90% |
| 1 Yıllık Değişim | -6.25% |
| 3 Yıllık Değişim | 85.19% |
| 5 Yıllık Değişim | -54.06% |
| Halka arzdan bu yana değişim | -89.20% |
Son Haberler & Güncellemeler
Analiz Makalesi • Aug 14
US$6.00 - That's What Analysts Think Neuronetics, Inc. (NASDAQ:STIM) Is Worth After These Results
Neuronetics, Inc. ( NASDAQ:STIM ) just released its quarterly report and things are looking bullish. Revenues and...
Anlatı Güncellemesi • Aug 13
STIM: Vertically Integrated Interventional Psychiatry Platform Will Drive Future Repricing
Analysts lifted their price target on Neuronetics to $5.25 from $4.33, citing the company’s expanded vertically integrated mental health platform following the Greenbrook TMS acquisition and the potential they see in interventional psychiatry adoption. What’s in the News for Neuronetics Neuronetics narrowed full year 2026 total revenue guidance to a range of US$160 million to US$164 million, compared with the prior range of US$160 million to US$166 million.Recent updates
Analiz Makalesi • Aug 14
US$6.00 - That's What Analysts Think Neuronetics, Inc. (NASDAQ:STIM) Is Worth After These Results
Neuronetics, Inc. ( NASDAQ:STIM ) just released its quarterly report and things are looking bullish. Revenues and...Anlatı Güncellemesi • Aug 13
STIM: Vertically Integrated Interventional Psychiatry Platform Will Drive Future Repricing
Analysts lifted their price target on Neuronetics to $5.25 from $4.33, citing the company’s expanded vertically integrated mental health platform following the Greenbrook TMS acquisition and the potential they see in interventional psychiatry adoption. What’s in the News for Neuronetics Neuronetics narrowed full year 2026 total revenue guidance to a range of US$160 million to US$164 million, compared with the prior range of US$160 million to US$166 million.Seeking Alpha • Jul 17
Neuronetics Could Double, But The Balance Sheet May Crack First
Summary Neuronetics, Inc. is rated Hold due to liquidity and dilution risks despite potential undervaluation relative to growth prospects. STIM’s NeuroStar segment offers high-margin, recurring revenue, while Greenbrook clinics provide growth but suffer from low margins and cash burn. Base case valuation approximates the current market price; the bull case offers upside if NeuroStar accelerates growth and Greenbrook clinics reach break-even. Resolution of the March 2027 debt covenant or a price decline below $1 would prompt reconsideration of a long position. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 18
STIM: Policy Shift Allowing Wider TMS Use Will Drive Future Repricing
Analysts kept their Neuronetics price target steady around $4.33, with minor adjustments to the discount rate, profit margin assumptions, and future P/E expectations. These changes reflect updated views on risk and profitability rather than a shift in the core valuation story.Anlatı Güncellemesi • Jun 03
STIM: Policy Expansion And Leadership Shift Will Drive Future Repricing
Analysts have trimmed their price target on Neuronetics by $4, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E that, taken together, indicate a more measured outlook for the stock. What's in the News Guidance: Neuronetics issued earnings guidance for full year 2026, projecting total revenue of US$160 million to US$166 million and a gross margin of 47% to 49%.Anlatı Güncellemesi • May 01
STIM: Recalibrated Assumptions And Policy Tailwinds Will Drive Future Repricing
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, profit margins, and future P/E expectations. This results in a slightly lower fair value outlook while keeping the core narrative largely intact.Anlatı Güncellemesi • Apr 16
STIM: Reset Expectations And Higher Discount Rate Will Support Future Repricing
Analysts have lowered their price target on Neuronetics by $4, reflecting updated views on the discount rate, profit margin assumptions, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts view the revised price target as closer to their current assumptions on discount rates and future P/E levels, which they see as a more grounded reflection of Neuronetics' risk profile.
Yeni Anlatı • Apr 04
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
Catalysts About Neuronetics Neuronetics develops and operates NeuroStar TMS systems and Greenbrook mental health clinics that provide device based and drug based treatments for depression and other conditions. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Apr 02
STIM: Updated Discount Rate Assumptions Will Support Bullish Repricing Over Time
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, margins, and future P/E. This has led to a slightly more cautious outlook on the shares.
Yeni Anlatı • Mar 18
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
Catalysts About Neuronetics Neuronetics develops and commercializes NeuroStar TMS systems and operates Greenbrook clinics that provide device based and drug treatments for mental health conditions, including treatment resistant depression. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 18
STIM: Leadership Transition And 2026 Revenue Outlook Will Support Bullish Repricing
Analysts have cut their price target on Neuronetics to $4.33 from $6.50, citing updated assumptions for lower revenue growth at 12.65%, a higher discount rate of 10.04%, a slightly higher profit margin of 13.36%, and a reduced future P/E of 16.22x. What's in the News Neuronetics plans a leadership transition with Dan Reuvers appointed as the next Chief Executive Officer, effective March 23, 2026, while current CEO Keith Sullivan is scheduled to step down on March 23, 2026 and retire on March 31, 2026 after roughly five and a half years leading the company (Key Developments).Analiz Makalesi • Jan 07
There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted Revenues Despite A 25% Share Price Rise
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...Analiz Makalesi • Dec 13
Would Neuronetics (NASDAQ:STIM) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Nov 14
Slammed 29% Neuronetics, Inc. (NASDAQ:STIM) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Neuronetics, Inc. ( NASDAQ:STIM ) shares are down a considerable 29% in the last...Analiz Makalesi • Nov 06
The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Neuronetics, Inc. ( NASDAQ:STIM ) last week reported its latest third-quarter results, which makes it a good time for...Analiz Makalesi • Aug 26
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 29% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shares have had a horrible month, losing 29% after a relatively good period...Analiz Makalesi • Aug 07
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results
NasdaqGM:STIM 1 Year Share Price vs Fair Value Explore Neuronetics's Fair Values from the Community and select yours...Analiz Makalesi • May 15
Why We Think Neuronetics, Inc.'s (NASDAQ:STIM) CEO Compensation Is Not Excessive At All
Key Insights Neuronetics' Annual General Meeting to take place on 22nd of May Total pay for CEO Keith Sullivan includes...Analiz Makalesi • May 09
Neuronetics, Inc. (NASDAQ:STIM) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a good week for Neuronetics, Inc. ( NASDAQ:STIM ) shareholders, because the company has just released its...Analiz Makalesi • May 04
Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors
Neuronetics, Inc. ( NASDAQ:STIM ) shares have continued their recent momentum with a 30% gain in the last month alone...
Yeni Anlatı • Apr 09
TMS Acquisition And BMP Expansion Will Transform Treatment Delivery
The acquisition of Greenbrook and expansion of the BMP program are expected to significantly boost revenue through increased patient access and operational efficiency.Seeking Alpha • Mar 30
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Summary Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025. Despite risks like high volatility and competition, Neuronetics' strong market position and growth potential make it a promising investment. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 06
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 69% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 69% in...Analiz Makalesi • Feb 10
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) may be thrilled to learn that the analysts have just delivered a...Analiz Makalesi • Jan 11
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 43% in...Analiz Makalesi • Jan 02
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Nov 18
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Market forces rained on the parade of Neuronetics, Inc. ( NASDAQ:STIM ) shareholders today, when the analysts...Analiz Makalesi • Nov 05
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Those holding Neuronetics, Inc. ( NASDAQ:STIM ) shares would be relieved that the share price has rebounded 28% in the...Analiz Makalesi • Aug 13
Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
The Neuronetics, Inc. ( NASDAQ:STIM ) share price has fared very poorly over the last month, falling by a substantial...Analiz Makalesi • May 24
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
Key Insights Neuronetics will host its Annual General Meeting on 30th of May Total pay for CEO Keith Sullivan includes...Analiz Makalesi • May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) had a terrible week, as shares crashed 28% to US$2.55 in the week...Seeking Alpha • May 09
Neuronetics: Reality Set In
Summary Neuronetics' share price dropped after reporting soft Q1 2024 results, with weak system sales undermining strong treatment demand. Neuronetics' losses remain relatively large, and the company's balance sheet provides it with limited flexibility. The stock may have further to fall if Neuronetics is not able to demonstrate a clear path to profitability in the coming quarters. Read the full article on Seeking AlphaAnaliz Makalesi • May 08
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • May 01
Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Hissedar Getirileri
| STIM | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -8.3% | 1.5% | -1.2% |
| 1Y | -6.3% | -11.6% | 18.3% |
Getiri vs. Endüstri: STIM geçen yıl % -11.6 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: STIM geçen yıl % 18.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| STIM volatility | |
|---|---|
| STIM Average Weekly Movement | 19.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: STIM hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: STIM 'nin haftalık oynaklığı ( 20% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2001 | 658 | Dan Reuvers | neurostar.com/neuronetics |
Neuronetics, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda nöro-sağlık bozuklukları olan hastalar için ofis içi tedaviler sağlamaktadır. Şirket, majör depresif bozukluğu olan yetişkin hastaları tedavi etmek için non-invaziv ve sistemik olmayan ofis tabanlı bir tedavi olan NeuroStar Gelişmiş Terapi Sistemi sunmaktadır. NeuroStar Gelişmiş Terapi Sistemi, beynin ruh haliyle ilişkili belirli bölgelerini uyarmak için tasarlanmış elektrik akımlarını indükleyen darbeli, MRI gücünde bir manyetik alan oluşturmak için transkraniyal manyetik stimülasyon kullanır.
Neuronetics, Inc. Temel Bilgiler Özeti
| STIM temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$228.59m |
| Kazançlar(TTM) | -US$30.43m |
| Gelir(TTM) | US$155.10m |
1.5x
P/S Oranı-7.5x
F/K OranıSTIM aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| STIM gelir tablosu (TTM) | |
|---|---|
| Gelir | US$155.10m |
| Gelir Maliyeti | US$78.51m |
| Brüt Kâr | US$76.59m |
| Diğer Giderler | US$107.02m |
| Kazançlar | -US$30.43m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.40 |
| Brüt Marj | 49.38% |
| Net Kâr Marjı | -19.62% |
| Borç/Özkaynak Oranı | 284.3% |
STIM uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/24 09:55 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Neuronetics, Inc. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Sam Eiber | BTIG |
| William Plovanic | Canaccord Genuity |
| Daniel Stauder | Citizens JMP Securities, LLC |